Aurobindo Pharma Posts 16.3% Revenue Growth to Rs 9,150 Crore in Q1 FY27

Aurobindo Pharma's Q1 FY27 results signal that capacity investments in US generics and injectables are beginning to translate into measurable margin improvement, a read that carries weight for plant heads and QA directors tracking Indian CDMO competitiveness heading into the second half of the fiscal year.

The company reported consolidated revenue of Rs 9,150 crore for the quarter ended June 2026, a 16.3% increase year-on-year. Net profit rose 25.2% to Rs 1,032 crore, outpacing topline growth, a spread that typically reflects operating leverage from higher asset utilisation rather than one-time gains.

EBITDA climbed 20% year-on-year to Rs 1,924 crore, with EBITDA margin expanding 60 basis points to 21.0%. For operations and QA leadership, margin expansion at this scale, alongside double-digit revenue growth, points to improved throughput efficiency across manufacturing sites rather than cost reduction alone.

Aurobindo's injectable and US generics segments have been the primary drivers of its recent capital expenditure cycle. Sustained revenue growth at this rate, combined with margin improvement, suggests those investments are clearing the process validation and regulatory clearance hurdles that typically delay capacity monetisation in sterile manufacturing.

For regulatory affairs leads, the profit trajectory is worth reading against Aurobindo's ongoing site compliance posture with the US FDA, any unresolved observations at key injectable facilities would constrain the revenue upside that these numbers imply is now flowing through.

The 60-basis-point EBITDA margin improvement, if sustained through Q2 FY27, would represent a meaningful shift in Aurobindo's cost structure relative to its Indian generics peers and reinforce its positioning as a volume-scale CDMO for the US market.

Source: Media4Growth via Indian Pharma Post, 5 August 2026.